<DOC>
	<DOCNO>NCT01968070</DOCNO>
	<brief_summary>The main purpose study evaluate safety well body handle single multiple dos increase strength study drug , LY3127760 . This study include three part . Part 3 may initiate sponsor 's discretion , base data Part 2 . Participants enroll 1 3 study part . This study last approximately 7 13 week , depend part . Screening must complete within 28 day prior enrollment .</brief_summary>
	<brief_title>A Study LY3127760 Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Overtly healthy male female determine medical history physical examination Male participant agree use reliable method birth control study 3 month follow last dose investigational product Female participant childbearing potential Have body mass index 18.5 32 kilogram per square meter ( kg/m^2 ) inclusive Are normotensive ( defined supine systolic blood pressure ( BP ) less 140 millimeter mercury [ mm Hg ] diastolic BP le 90 mm Hg ) without use antihypertensive Have know allergy LY3127760 , related compound component formulation , celecoxib sulfonamide , history significant atopy . Participants know aspirin allergy allergic reaction nonsteroidal antiinflammatory drug ( NSAIDs ) also exclude Have current prior history significant gastrointestinal illness peptic ulcer disease , gastrointestinal ( GI ) bleeding , chronic gastritis , inflammatory bowel disease chronic diarrhea Have evidence chronic liver disease , include limited chronic alcoholic disease , nonalcoholic steatohepatitis , recent history ( within 3 month screen ) acute viral hepatitis chronic autoimmune hepatitis Have use NSAIDs , celecoxib , aspirin acetaminophen ( dose great 1 gram per day ) , anticoagulant antiplatelet agent within 14 day admission Part 2 Part 3 Have 1 plus pretrial pitting edema 2 plus ankle pedal edema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>